Sr. Manager, Early Talent & Recruitment Marketing at Legend Biotech

Franklin Township, New Jersey, United States

Legend Biotech Logo
Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, PharmaceuticalsIndustries

Requirements

  • A bachelor’s degree is required, preferably in Human Resources
  • Minimum 5+ years in Talent Acquisition, Early Talent/University Recruitment, or Recruitment Marketing, with experience in a global environment
  • Strong understanding of early talent programs and university partnerships within biotech, pharma, or life sciences
  • Experience working with multi-regional teams

Responsibilities

  • Develop and maintain a 3–5-year Global Early Talent Roadmap (interns, co-ops, new grads, post-docs) aligned to workforce plans and growth priorities
  • Design and run the U.S. internship/co-op program with clear intake calendar, manager toolkit, evaluation survey, and conversion tracking
  • Build the “early talent → entry-level” attraction and conversion model to drive Tier 1/Tier 2 university talent into open roles in R&D, Manufacturing, and G&A
  • Partner with TA Business Partners (TABPs) and hiring managers to activate demand for early talent in business units
  • Create and maintain a central early-talent/Hi-Po database consolidating current-year and prior-year early-career hires (fresh grads + post-docs) across US/EU/CN
  • Develop Hi-Po selection criteria in partnership with HRBPs and Talent Development to distinguish high-potential early hires from standard hires
  • Deliver quarterly reports to TA LT/HRLT on early talent progress, diversity of sources, and Hi-Po movement; support Chairman/senior leader showcase meetings featuring selected talent
  • Lead TA’s employer branding and recruitment marketing strategy in partnership with Culture, Corporate Communications, and TA Operations
  • Embed the EVP output into job templates, ATS emails, career site content, campus materials, and social campaigns
  • Develop candidate attraction decks (corporate, BU, regional) to enable recruiters and TABPs
  • Track and report channel performance (LinkedIn, campus platforms, etc.) and recommend other channels
  • Run the TA newsletter / TA storytelling cadence with cross-regional contributions
  • Build and maintain a central TA asset library (SharePoint) with reusable marketing assets, EVP-based content, and program materials for recruiters
  • Collaborate with Corporate Communications on brand or culture campaigns annually (e.g., Life at Legend, Women in STEM, Early Talent at Legend)

Skills

Talent Acquisition
Recruitment Marketing
Employer Branding
Early Talent Programs
Internship Programs
Co-op Programs
Strategic Planning
Roadmap Development
Program Management
Global Talent Strategy

Legend Biotech

Develops and commercializes cell therapies

About Legend Biotech

Legend Biotech develops and commercializes cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates in the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's cells to combat cancer. Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments.

Franklin Township, New JerseyHeadquarters
2014Year Founded
$146.4MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
1,001-5,000Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Paid Sick Leave
Paid Holidays
Remote Work Options

Risks

Increased competition from Amgen's Imdelltra may impact CAR-T therapy focus.
Collaboration with Multiply Labs may face technological challenges, delaying production timelines.
Financial strain from new R&D facility could affect operational focus if advancements lag.

Differentiation

Legend Biotech focuses on novel cell therapies for oncology, including CAR-T and NK cells.
The company is technology agnostic, exploring multiple platforms for effective cancer treatments.
Legend Biotech's CARVYKTI® is the first BCMA-targeted CAR-T therapy approved for second-line use.

Upsides

Recent FDA and European approvals for CARVYKTI® expand its market reach in multiple myeloma.
New R&D facility in Philadelphia boosts innovation in next-generation cell therapies.
Alan Bash's appointment could accelerate CARVYKTI®'s growth and market penetration.

Land your dream remote job 3x faster with AI